Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02818777 · ClinicalTrials.gov registry record · Phase 2
A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT02818777 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 13 participants.
The verdict
NCT02818777, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The major purpose of the Stage 1 is to study the safety and tolerability of the proposed dosage regimen of the study drug. The form of cannabidiol (CBD) used in this study is GWP42003, supplied by GW Pharmaceuticals. The dosage regime is based on their experience. This is an open label study in 10 subjects, during which the dose is gradually increased to the manufacturers recommended target dose, with tolerability being evaluated at each dose level. Based on the response of subjects in the Stage 1, a target dose is determined for the next stage. Standardized tools will be administered to study both tolerability and efficacy. Efficacy assessments are simply explorative, and are done to look for an effect that warrants specific or different evaluation in the next stage.
Interventions
- DRUG cannabidiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2016-10 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02818777
The ClinicalTrials.gov registry entry for NCT02818777 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cannabidiol is the first listed.
NCT02818777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02818777 about?
NCT02818777 is a clinical study titled "A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease". The major purpose of the Stage 1 is to study the safety and tolerability of the proposed dosage regimen of the study drug. The form of cannabidiol (CBD) used in this study is GWP42003, supplied by GW Pharmaceuticals. The dosage regime is based on their experience. This is an open label study in 10 s...
What is the current status of trial NCT02818777?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2016-10. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02818777?
The interventions under investigation include: cannabidiol (DRUG).
Who is sponsoring clinical trial NCT02818777?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.